EC upgrades approval for J&J’s Rybrevant/chemotherapy combination in NSCLC
Rybrevant has been granted a Type II approval extension to treat NSCLC with EGFR mutations following the failure of TKI therapy.
Rybrevant has been granted a Type II approval extension to treat NSCLC with EGFR mutations following the failure of TKI therapy.
What's Your Reaction?
